{"id":494798,"date":"2021-05-18T07:04:41","date_gmt":"2021-05-18T11:04:41","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/oxford-biomedica-upgrades-financial-guidance-for-supply-agreement-with-astrazeneca-for-manufacture-of-covid-19-vaccine\/"},"modified":"2021-05-18T07:04:41","modified_gmt":"2021-05-18T11:04:41","slug":"oxford-biomedica-upgrades-financial-guidance-for-supply-agreement-with-astrazeneca-for-manufacture-of-covid-19-vaccine","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/oxford-biomedica-upgrades-financial-guidance-for-supply-agreement-with-astrazeneca-for-manufacture-of-covid-19-vaccine\/","title":{"rendered":"Oxford Biomedica upgrades financial guidance for supply agreement with AstraZeneca for manufacture of COVID-19 Vaccine"},"content":{"rendered":"
\n

\n The information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the Market Abuse Regulation (EU) No. 596\/2014<\/em>
\n (as it forms part of domestic law by virtue of the European Union (Withdrawal) Act 2018)<\/em>
\n . Upon the publication of this announcement via the Regulatory Information Service, this inside information is now considered to be in the public domain<\/em>
\n .<\/em>\n <\/p>\n

\n Oxford <\/strong>
\n Biom<\/strong>
\n edica<\/strong>
\n upgrades <\/strong>
\n financial <\/strong>
\n guidance for<\/strong>
\n s<\/strong>
\n upply<\/strong>
\n a<\/strong>
\n greement with <\/strong>
\n AstraZeneca<\/strong>
\n for manufacture of<\/strong>
\n COVID<\/strong>
\n -19 <\/strong>
\n V<\/strong>
\n accine<\/strong>\n <\/p>\n

\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0
Oxford, UK \u2013 <\/strong>18<\/strong>May<\/strong>,<\/strong> 20<\/strong>2<\/strong>1<\/strong>: <\/strong>Oxford Biomedica plc (LSE:OXB) (\u201cOxford Biomedica\u201d or \u201cthe Group\u201d), a leading gene and cell therapy group, announced today an update on the 18 month supply agreement signed with AstraZeneca UK Ltd (\u201cAstraZeneca\u201d) in September 2020.<\/p>\n

Following successful manufacture of large-scale batches of AstraZeneca\u2019s COVID-19 Vaccine, AstraZeneca has today committed to an increase in the number of batches required from Oxford Biomedica in the second half of 2021. As a result of this, the Group is raising revenue guidance for expected cumulative revenues from AstraZeneca by the end of 2021 from in excess of \u00a350 million to in excess of \u00a3100 million, and as a result expects significant growth in Group Operating EBITDA in the year ending 2021.<\/p>\n

As previously guided, Oxford Biomedica does not expect the commitment to AstraZeneca for vaccine production to have any impact on the Group\u2019s current partnerships or ability to secure and support additional new partnerships in the cell and gene therapy field.<\/p>\n

\n Background to the agreement with AstraZeneca <\/strong>
\n
Oxford Biomedica announced an 18 month supply agreement in September 2020 under a three year Master Supply and Development Agreement (\u201cthe Agreement\u201d) with AstraZeneca UK Ltd (\u201cAstraZeneca\u201d) for large-scale commercial manufacture of the adenovirus vector-based COVID-19 vaccine, AZD1222. (see LINK<\/u><\/a>).\u00a0\u00a0<\/p>\n

\n John Dawson, Chief <\/strong>
\n Executive Officer of Oxford <\/strong>
\n Biom<\/strong>
\n edica<\/strong>
\n , said:<\/strong>
\n \u201c<\/em>
\n Everyone involved with production of <\/em>
\n the COVID-19 Vaccine<\/em>
\n can be truly proud of their achievement in <\/em>
\n manufacturing<\/em>
\n batches of vaccine from our <\/em>
\n Oxbox<\/em>
\n manufacturing<\/em>
\n facility. We are delighted to be <\/em>
\n a key supplier of the vaccine<\/em>
\n and<\/em>
\n t<\/em>
\n he<\/em>
\n Group is<\/em>
\n proud <\/em>
\n to be <\/em>
\n part of <\/em>
\n this<\/em>
\n world-leading<\/em>
\n vaccination project that <\/em>
\n is<\/em>
\n saving many lives<\/em>
\n .<\/em>
\n \u201d <\/em>\n <\/p>\n

\n -Ends-<\/strong>\n <\/p>\n

\n Enquiries:<\/strong>\n <\/p>\n

\n Oxford <\/strong>
\n Biomedica<\/strong>
\n plc<\/strong>\n <\/p>\n

John Dawson, Chief Executive Officer\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0T: +44 (0)1865 783 000
Stuart Paynter, Chief Financial Officer\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0T: +44 (0)1865 783 000
Catherine Isted, Head of Corporate Development & IR \u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0T: +44 (0)1865 954 161 \/ E: ir@oxb.com<\/p>\n

\n Consilium<\/strong>
\n Strategic Communications<\/strong>\n <\/p>\n

Mary-Jane Elliott \/ Matthew Neal\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0T: +44 (0)20 3709 5700<\/p>\n

\n About Oxford <\/strong>
\n Biomedica<\/strong>\n <\/p>\n

Oxford Biomedica (LSE:OXB) is a leading, fully integrated, cell and gene therapy group focused on developing life changing treatments for serious diseases. Oxford Biomedica and its subsidiaries (the “Group”) have built a sector leading lentiviral vector delivery platform (LentiVector\u00ae<\/sup>), which the Group leverages to develop in vivo and ex vivo products both in-house and with partners. The Group has created a valuable proprietary portfolio of gene and cell therapy product candidates in the areas of oncology, ophthalmology, CNS disorders and liver diseases. The Group has also entered into a number of partnerships, including with Novartis, Bristol Myers Squibb, Sio Gene Therapies, Orchard Therapeutics, Santen, Beam Therapeutics, Boehringer Ingelheim, the UK Cystic Fibrosis Gene Therapy Consortium and Imperial Innovations, through which it has long-term economic interests in other potential gene and cell therapy products. Additionally the group has signed a 3 year master supply and development agreement with AstraZeneca for large-scale manufacturing of the adenoviral based COVID-19 vaccine, AZD1222. Oxford Biomedica is based across several locations in Oxfordshire, UK and employs more than 670 people. Further information is available at www.oxb.com<\/u><\/a><\/p>\n

The person who arranged for the release of this announcement on behalf of Oxford Biomedica plc was John Dawson, Chief Executive Officer.<\/p>\n

\n
\n
\n \n <\/div>\n

<\/div>\n","protected":false},"excerpt":{"rendered":"

The information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the Market Abuse Regulation (EU) No. 596\/2014 (as it forms part of domestic law by virtue of the European Union (Withdrawal) Act 2018) . Upon the publication of this announcement via the Regulatory Information Service, this inside information is now considered to be in the public domain . Oxford Biom edica upgrades financial guidance for s upply a greement with AstraZeneca for manufacture of COVID -19 V accine \u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0Oxford, UK \u2013 18May, 2021: Oxford Biomedica plc (LSE:OXB) (\u201cOxford Biomedica\u201d or \u201cthe Group\u201d), a leading gene and cell therapy group, announced today an update on the 18 month supply agreement signed with AstraZeneca … <\/p>\n

Continue reading “Oxford Biomedica upgrades financial guidance for supply agreement with AstraZeneca for manufacture of COVID-19 Vaccine”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-494798","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nOxford Biomedica upgrades financial guidance for supply agreement with AstraZeneca for manufacture of COVID-19 Vaccine - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/oxford-biomedica-upgrades-financial-guidance-for-supply-agreement-with-astrazeneca-for-manufacture-of-covid-19-vaccine\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Oxford Biomedica upgrades financial guidance for supply agreement with AstraZeneca for manufacture of COVID-19 Vaccine - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"The information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the Market Abuse Regulation (EU) No. 596\/2014 (as it forms part of domestic law by virtue of the European Union (Withdrawal) Act 2018) . Upon the publication of this announcement via the Regulatory Information Service, this inside information is now considered to be in the public domain . Oxford Biom edica upgrades financial guidance for s upply a greement with AstraZeneca for manufacture of COVID -19 V accine \u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0Oxford, UK \u2013 18May, 2021: Oxford Biomedica plc (LSE:OXB) (\u201cOxford Biomedica\u201d or \u201cthe Group\u201d), a leading gene and cell therapy group, announced today an update on the 18 month supply agreement signed with AstraZeneca … Continue reading "Oxford Biomedica upgrades financial guidance for supply agreement with AstraZeneca for manufacture of COVID-19 Vaccine"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/oxford-biomedica-upgrades-financial-guidance-for-supply-agreement-with-astrazeneca-for-manufacture-of-covid-19-vaccine\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-05-18T11:04:41+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMDQ5NTUwOCM0MDA5NDE3MTQjNzAwMDEwNTky\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/oxford-biomedica-upgrades-financial-guidance-for-supply-agreement-with-astrazeneca-for-manufacture-of-covid-19-vaccine\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/oxford-biomedica-upgrades-financial-guidance-for-supply-agreement-with-astrazeneca-for-manufacture-of-covid-19-vaccine\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Oxford Biomedica upgrades financial guidance for supply agreement with AstraZeneca for manufacture of COVID-19 Vaccine\",\"datePublished\":\"2021-05-18T11:04:41+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/oxford-biomedica-upgrades-financial-guidance-for-supply-agreement-with-astrazeneca-for-manufacture-of-covid-19-vaccine\\\/\"},\"wordCount\":606,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/oxford-biomedica-upgrades-financial-guidance-for-supply-agreement-with-astrazeneca-for-manufacture-of-covid-19-vaccine\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=MTAwMDQ5NTUwOCM0MDA5NDE3MTQjNzAwMDEwNTky\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/oxford-biomedica-upgrades-financial-guidance-for-supply-agreement-with-astrazeneca-for-manufacture-of-covid-19-vaccine\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/oxford-biomedica-upgrades-financial-guidance-for-supply-agreement-with-astrazeneca-for-manufacture-of-covid-19-vaccine\\\/\",\"name\":\"Oxford Biomedica upgrades financial guidance for supply agreement with AstraZeneca for manufacture of COVID-19 Vaccine - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/oxford-biomedica-upgrades-financial-guidance-for-supply-agreement-with-astrazeneca-for-manufacture-of-covid-19-vaccine\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/oxford-biomedica-upgrades-financial-guidance-for-supply-agreement-with-astrazeneca-for-manufacture-of-covid-19-vaccine\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=MTAwMDQ5NTUwOCM0MDA5NDE3MTQjNzAwMDEwNTky\",\"datePublished\":\"2021-05-18T11:04:41+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/oxford-biomedica-upgrades-financial-guidance-for-supply-agreement-with-astrazeneca-for-manufacture-of-covid-19-vaccine\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/oxford-biomedica-upgrades-financial-guidance-for-supply-agreement-with-astrazeneca-for-manufacture-of-covid-19-vaccine\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/oxford-biomedica-upgrades-financial-guidance-for-supply-agreement-with-astrazeneca-for-manufacture-of-covid-19-vaccine\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=MTAwMDQ5NTUwOCM0MDA5NDE3MTQjNzAwMDEwNTky\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=MTAwMDQ5NTUwOCM0MDA5NDE3MTQjNzAwMDEwNTky\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/oxford-biomedica-upgrades-financial-guidance-for-supply-agreement-with-astrazeneca-for-manufacture-of-covid-19-vaccine\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Oxford Biomedica upgrades financial guidance for supply agreement with AstraZeneca for manufacture of COVID-19 Vaccine\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Oxford Biomedica upgrades financial guidance for supply agreement with AstraZeneca for manufacture of COVID-19 Vaccine - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/oxford-biomedica-upgrades-financial-guidance-for-supply-agreement-with-astrazeneca-for-manufacture-of-covid-19-vaccine\/","og_locale":"en_US","og_type":"article","og_title":"Oxford Biomedica upgrades financial guidance for supply agreement with AstraZeneca for manufacture of COVID-19 Vaccine - Market Newsdesk","og_description":"The information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the Market Abuse Regulation (EU) No. 596\/2014 (as it forms part of domestic law by virtue of the European Union (Withdrawal) Act 2018) . Upon the publication of this announcement via the Regulatory Information Service, this inside information is now considered to be in the public domain . Oxford Biom edica upgrades financial guidance for s upply a greement with AstraZeneca for manufacture of COVID -19 V accine \u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0Oxford, UK \u2013 18May, 2021: Oxford Biomedica plc (LSE:OXB) (\u201cOxford Biomedica\u201d or \u201cthe Group\u201d), a leading gene and cell therapy group, announced today an update on the 18 month supply agreement signed with AstraZeneca … Continue reading \"Oxford Biomedica upgrades financial guidance for supply agreement with AstraZeneca for manufacture of COVID-19 Vaccine\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/oxford-biomedica-upgrades-financial-guidance-for-supply-agreement-with-astrazeneca-for-manufacture-of-covid-19-vaccine\/","og_site_name":"Market Newsdesk","article_published_time":"2021-05-18T11:04:41+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMDQ5NTUwOCM0MDA5NDE3MTQjNzAwMDEwNTky","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/oxford-biomedica-upgrades-financial-guidance-for-supply-agreement-with-astrazeneca-for-manufacture-of-covid-19-vaccine\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/oxford-biomedica-upgrades-financial-guidance-for-supply-agreement-with-astrazeneca-for-manufacture-of-covid-19-vaccine\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Oxford Biomedica upgrades financial guidance for supply agreement with AstraZeneca for manufacture of COVID-19 Vaccine","datePublished":"2021-05-18T11:04:41+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/oxford-biomedica-upgrades-financial-guidance-for-supply-agreement-with-astrazeneca-for-manufacture-of-covid-19-vaccine\/"},"wordCount":606,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/oxford-biomedica-upgrades-financial-guidance-for-supply-agreement-with-astrazeneca-for-manufacture-of-covid-19-vaccine\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMDQ5NTUwOCM0MDA5NDE3MTQjNzAwMDEwNTky","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/oxford-biomedica-upgrades-financial-guidance-for-supply-agreement-with-astrazeneca-for-manufacture-of-covid-19-vaccine\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/oxford-biomedica-upgrades-financial-guidance-for-supply-agreement-with-astrazeneca-for-manufacture-of-covid-19-vaccine\/","name":"Oxford Biomedica upgrades financial guidance for supply agreement with AstraZeneca for manufacture of COVID-19 Vaccine - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/oxford-biomedica-upgrades-financial-guidance-for-supply-agreement-with-astrazeneca-for-manufacture-of-covid-19-vaccine\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/oxford-biomedica-upgrades-financial-guidance-for-supply-agreement-with-astrazeneca-for-manufacture-of-covid-19-vaccine\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMDQ5NTUwOCM0MDA5NDE3MTQjNzAwMDEwNTky","datePublished":"2021-05-18T11:04:41+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/oxford-biomedica-upgrades-financial-guidance-for-supply-agreement-with-astrazeneca-for-manufacture-of-covid-19-vaccine\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/oxford-biomedica-upgrades-financial-guidance-for-supply-agreement-with-astrazeneca-for-manufacture-of-covid-19-vaccine\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/oxford-biomedica-upgrades-financial-guidance-for-supply-agreement-with-astrazeneca-for-manufacture-of-covid-19-vaccine\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMDQ5NTUwOCM0MDA5NDE3MTQjNzAwMDEwNTky","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMDQ5NTUwOCM0MDA5NDE3MTQjNzAwMDEwNTky"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/oxford-biomedica-upgrades-financial-guidance-for-supply-agreement-with-astrazeneca-for-manufacture-of-covid-19-vaccine\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Oxford Biomedica upgrades financial guidance for supply agreement with AstraZeneca for manufacture of COVID-19 Vaccine"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/494798","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=494798"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/494798\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=494798"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=494798"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=494798"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}